Veradermics MANE
NYSE MANE
$148.63 +4.68 (+3.25%)
As of: Nov 10, 2026 · 3:59 PM EST

Veradermics (MANE) Preferred Stock Liabilities (2024 - 2025)

Updated

Veradermics (MANE) recorded Preferred Stock Liabilities of $266.33 million in Q4 2025, up 158.2% from $103.15 million a year earlier.

Analysis

Veradermics (MANE) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends

Starting with Q4 2024, Veradermics' Preferred Stock Liabilities history includes 4 quarters.

  • Across earlier years, Preferred Stock Liabilities came in at $103.15 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn -
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn -
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Veradermics 6.01 Bn 4.61 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 266.33 Mn
Jun 30, 2025 111.57 Mn
Mar 31, 2025 111.57 Mn
Dec 31, 2024 103.15 Mn
API Access

Veradermics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=MANE&period=max&api_key=YOUR_API_KEY